Author: CAPD

What Cost Plus Really Means for Americans’ Pharmacy Benefits

Recently, the White House held a listening session to discuss prescription drug prices and the role pharmacy benefit…

Q&A: Rx Rebates are Unrelated to Drug Prices

As a new year begins, many Americans – including Members of Congress – are rightly asking why drug…

Big Pharma Kicks Off 2024 with Higher Prices

As 2024 begins, it brings an all-too-familiar tradition from big drug companies: a tidal wave of price hikes…

A Call to Congress: Safeguard Affordable Prescription Drugs for Employers and Patients

The stakes have rarely been higher for Americans struggling with high drug prices. As the House and Senate…

Unions and employers speak out against costly PBM restrictions

Labor unions are making headlines across the country this fall – and not just due to high-profile strikes…

Bottom Line: Employers Strongly Value Their PBMs

This fall, CAPD released a groundbreaking new poll showing that employers strongly value their PBMs. By high margins,…

Union households: lawmakers must protect our pharmacy benefits

New research out today from CAPD, conducted by Hart Research Associates, shows how strongly union households value their…

Conservatives Agree: Restricting Pharmacy Benefits Will Harm Patients, Taxpayers

GOP candidates will soon take the stage for one of the biggest political moments of the year: the…

Big Pharma is Playing a Dangerous Game with GLP-1s

It’s hard to miss the recent headlines about new weight-loss drugs like Ozempic and Wegovy. Called GLP-1s, these…

How Big Pharma’s Product Hops Hurt HIV/AIDS Care

Over the last twenty years, new medications have dramatically changed the fight against HIV/AIDS. These medications – called…